AR108009A1 - Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b - Google Patents

Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b

Info

Publication number
AR108009A1
AR108009A1 ARP170100786A ARP170100786A AR108009A1 AR 108009 A1 AR108009 A1 AR 108009A1 AR P170100786 A ARP170100786 A AR P170100786A AR P170100786 A ARP170100786 A AR P170100786A AR 108009 A1 AR108009 A1 AR 108009A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
virus
hepatitis
antigen
antigens
Prior art date
Application number
ARP170100786A
Other languages
English (en)
Spanish (es)
Inventor
Castillo Mariela Vzquez
Hernndez Jorge Valds
Blanco Sonia Gonzlez
Santiago Jorge Agustn Aguiar
Nieto Gerardo Enrique Guilln
Arias Eduardo Pentn
Perez Enrique Iglesias
Mato Yadira Lobaina
Rubido Julio Csar Aguilar
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Publication of AR108009A1 publication Critical patent/AR108009A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ARP170100786A 2016-03-31 2017-03-30 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b AR108009A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2016000038A CU24454B1 (es) 2016-03-31 2017-03-14 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b

Publications (1)

Publication Number Publication Date
AR108009A1 true AR108009A1 (es) 2018-07-04

Family

ID=58671308

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170100786A AR108009A1 (es) 2016-03-31 2017-03-30 Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b

Country Status (18)

Country Link
US (2) US11491218B2 (enExample)
EP (1) EP3437654B1 (enExample)
JP (1) JP6981992B2 (enExample)
KR (1) KR20180125985A (enExample)
CN (1) CN109219449B (enExample)
AR (1) AR108009A1 (enExample)
AU (1) AU2017243136B2 (enExample)
BR (1) BR112018069738A2 (enExample)
CA (1) CA3017778A1 (enExample)
CU (1) CU24454B1 (enExample)
EA (1) EA201892212A1 (enExample)
ES (1) ES2965709T3 (enExample)
MX (1) MX2018011793A (enExample)
MY (1) MY202118A (enExample)
TW (1) TWI755383B (enExample)
UA (1) UA128952C2 (enExample)
WO (1) WO2017167317A1 (enExample)
ZA (1) ZA201806325B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020355020A1 (en) * 2019-09-23 2022-04-28 Ascendo Biotechnology, Inc. Biodegradable nanocomplex vaccines, methods for suppression of hepapitis B virus replication and hepapitis B virus surface antigen secretion
CU20200028A7 (es) 2020-04-20 2021-11-04 Ct Ingenieria Genetica Biotecnologia Nucleoproteína viral y formulaciones que la contienen
CN116218881B (zh) * 2022-10-21 2024-08-13 山东大学 一种治疗或者预防乙肝病毒的疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22290A1 (es) 1990-10-08 1995-01-31 Cigb Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
CU23002A1 (es) * 2000-12-01 2004-11-18 Ct Ingenieria Genetica Biotech Método de obtención de agregados antigénicos y su uso en formulaciones
CN1164331C (zh) * 2001-05-23 2004-09-01 中国人民解放军第二军医大学 一种人乙型肝炎核酸疫苗
CU23740A1 (es) 2009-09-29 2011-12-28 Ct Ingenieria Genetica Biotech Método de obtención de una formulación de antígenos del virus de la hepatitis b
CN110859961A (zh) * 2013-07-26 2020-03-06 复旦大学 病毒免疫治疗药物复合物在制备治疗hbv感染药物中的应用

Also Published As

Publication number Publication date
EP3437654B1 (en) 2023-09-20
ZA201806325B (en) 2020-08-26
EA201892212A1 (ru) 2019-03-29
HK1259329A1 (zh) 2019-11-29
MY202118A (en) 2024-04-04
CU20160038A7 (es) 2017-11-07
JP2019510064A (ja) 2019-04-11
ES2965709T3 (es) 2024-04-16
CN109219449B (zh) 2022-08-30
AU2017243136B2 (en) 2022-02-17
CU24454B1 (es) 2019-11-04
UA128952C2 (uk) 2024-12-11
WO2017167317A1 (es) 2017-10-05
US20220193228A1 (en) 2022-06-23
EP3437654A1 (en) 2019-02-06
US20200297840A1 (en) 2020-09-24
TWI755383B (zh) 2022-02-21
US11491218B2 (en) 2022-11-08
CN109219449A (zh) 2019-01-15
KR20180125985A (ko) 2018-11-26
CA3017778A1 (en) 2017-10-05
US11759517B2 (en) 2023-09-19
JP6981992B2 (ja) 2021-12-17
AU2017243136A1 (en) 2018-10-11
TW201735945A (zh) 2017-10-16
MX2018011793A (es) 2018-12-17
BR112018069738A2 (pt) 2019-02-05

Similar Documents

Publication Publication Date Title
PH12019550220A1 (en) Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
CL2017002230A1 (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsida del vhb.
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
WO2017191258A8 (en) INFLUENZA MRNA VACCINES
MX388408B (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv
PE20160686A1 (es) Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infeccion por virus de la hepatitis b
PH12020550924A1 (en) Heptatitis b virus (hbv) vaccines and uses thereof
EA202091513A1 (ru) Вакцины против вируса гепатита b (hbv) и их применение
UY37998A (es) Agentes antivirales contra la hepatitis b
NZ616304A (en) Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
UY37962A (es) Nuevas y altamente activas indol-2-carboxamidas sustituidas con amino-tiazol activas contra el virus de la hepatitis b (vhb)
HRP20210608T1 (hr) Postupci i pripravci za induciranje zaštitnog imuniteta protiv infekcije virusom humane imunodeficijencije
Li et al. Research progress of therapeutic vaccines for treating chronic hepatitis B
AR108009A1 (es) Composición farmacéutica que comprende los antígenos de la superficie y de la nucleocápsida del virus de la hepatitis b
WO2014205199A3 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
HRP20240163T1 (hr) Metode i pripravci za izazivanje zaštitnog imuniteta protiv infekcije filovirusom
CL2012003219A1 (es) Parapoxvirus recombinante que comprende un parapoxvirus y adn heterólogo derivado de un virus de la rabia; procedimiento de preparación de dicho parapoxvirus; composicion inmunogénica; uso de la composicion para inducir respuesta inmunitaria contra el virus de la rabia en un animal.
MX392311B (es) Arbovirus recodificado y vacunas.
UY38933A (es) Vacuna de partículas tipo virus del chicunguña y métodos para su uso
JP2019510064A5 (enExample)
CO6300962A2 (es) Una proteina de fusion que comprende proteina circumesporozoito para uso en una vacuna contra la malaria
MY191697A (en) Use of the pacap as a molecular adjuvant for vaccines
Bijani et al. Comparison of the efficacy of hepatitis B vaccination by different routes of immunization
HK40074158A (en) Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines

Legal Events

Date Code Title Description
FC Refusal